Sarepta price target lowered to $75 from $80 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Sarepta (SRPT) to $75 from $80 and keeps a Sell rating on the shares. Sarepta’s deal to ...
bovnews8h
Why Did H.C. Wainwright Give Energy Fuels Inc (UUUU) Stock Buy Rating?
On Friday, Energy Fuels Inc (UUUU) stock saw a modest uptick, ending the day at $7.29 which represents a slight increase of $0.49 or 7.21% from the prior close of $6.8. The stock opened at $7.1 and ...
bovnews8m
Geron Corp (GERN) Stock Settles at $4.07: What’s Contributing to This Price Point?
On Friday, Geron Corp (GERN) stock saw a decline, ending the day at $4.07 which represents a decrease of $-0.10 or -2.40% from the prior close of $4.17. The stock opened at $4.17 and touched a low of ...
Stocktwits on MSN1h
Novocure Stock Soars On Positive Pancreatic Cancer Trial Results, Retail Sentiment Surges
Shares of Novocure Ltd. skyrocketed over 55% on Monday afternoon, reaching levels last seen in August 2023, as the company ...
TipRanks on MSN3d
Splash Beverage price target lowered to 50c from $1 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Splash Beverage (SBEV) to 50c from $1 and keeps a Buy rating on the shares ...
Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat
WARMINSTER, Pa., Nov. 26, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: ABUS), (“Arbutus” or the “Company”), a clinical-stage ...
ETF Daily News1d
electroCore, Inc. Enters into At The Market Offering Agreement with H.C. Wainwright & Co., LLC
The Company clarified that they are not obligated to sell any Shares under this agreement. H.C. Wainwright & Co., LLC will act to sell the Shares based on electroCore’s instructions and within the ...
Promising Prospects for Cytokinetics: Aficamten’s Strong Phase 3 Results and Strategic Bayer Collaboration Drive Buy Rating
H.C. Wainwright analyst Joseph Pantginis has reiterated their bullish stance on CYTK stock, giving a Buy rating on November 25.Don't Miss our ...
Alector price target lowered to $7 from $35 at H.C. Wainwright
H.C. Wainwright analyst Andrew Fein lowered the firm’s price target on Alector (ALEC) to $7 from $35 and keeps a Buy rating ...
Nasdaq6d
Poseida Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright analyst Arthur He downgraded Poseida Therapeutics (PSTX) to Neutral from Buy with a price target of $9, down from $20, after Roche (RHHBY) agreed to acquire the company for $1.5B ...
Nasdaq7d
BridgeBio price target raised to $49 from $43 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on BridgeBio (BBIO) to $49 from $43 and keeps a Buy rating on the shares. Acoramidis received regulatory approval with the label underscoring ...
Seeking Alpha20d
Phunware stock slides after downgrade to Neutral at H.C. Wainwright
Phunware (NASDAQ:PHUN) shares retreated 11% in Tuesday late morning trading after H.C. Wainwright & Co. downgraded the application software company to Neutral from Buy, as analyst Scott Buck ...